☆ 4.7 Review

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

LEUKEMIA (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article Hematology

SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

Jose Luis Pinana et al.

Summary: This multicenter study observed SARS-CoV-2 antibody detection in allogeneic and autologous hematopoietic stem cell transplant recipients post-vaccination, with most recipients showing detectable antibodies. Factors associated with lower antibody detection included lymphopenia, active GvHD, and timing of vaccination in allo-HSCT; and non-Hodgkin's lymphoma and corticosteroid therapy in ASCT recipients. These findings suggest considerations for monitoring SARS-CoV-2 antibodies in immunocompromised patients following stem cell transplants.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹
Article Hematology

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard et al.

BLOOD (2022)

添加到收藏夹
Article Hematology

Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response

Patrick Reimann et al.

Summary: Patients with haemato-oncological malignancies have lower response rates to COVID-19 vaccination, with a heterologous booster vaccination showing promise in improving response rates, although efficacy varies and may result in mild adverse events.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹
Letter Hematology

Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

Amandine Le Bourgeois et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹
Letter Microbiology

Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant

Joshua Deerain et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2022)

添加到收藏夹
News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

添加到收藏夹
Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Article Immunology

Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT

Jan Styczynski et al.

Summary: This study assessed the attitude towards deferral of HCT/chemotherapy in asymptomatic patients with a positive assay for SARS-CoV-2. The results showed that centers were willing to defer cellular therapy for asymptomatic patients without previous COVID-19 disease and those who remained asymptomatic after a previous COVID-19 disease but still shed the virus. The willingness to defer treatment was higher for cellular therapy patients compared to noncellular therapy patients, and varied based on the type of hematological disease and treatment.

TRANSPLANT INFECTIOUS DISEASE (2022)

添加到收藏夹
Article Immunology

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Nikhil Ram-Mohan et al.

Summary: Measurement of SARS-CoV-2 RNA from the plasma of COVID-19 patients using digital polymerase chain reaction can predict disease severity, clinical deterioration, and extrapulmonary complications. It may guide patient triage and management effectively.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹
Article Immunology

Association Between SARS-CoV-2 RNAemia and Postacute Sequelae of COVID-19

Nikhil Ram-Mohan et al.

Summary: Determinants of Post-Acute Sequelae of COVID-19 are not known. This study found that the presence of viral RNA in blood (RNAemia) at presentation successfully predicted the occurrence of post-acute symptoms, independent of patient demographics, disease severity, and length of symptoms.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹
Editorial Material Hematology

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Cristina Bagacean et al.

BLOOD ADVANCES (2022)

添加到收藏夹
Article Immunology

The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection

Allen W. Zhang et al.

Summary: The use of G-CSF in cancer patients with COVID-19 may increase the risk of hospitalization, respiratory failure, and death. Careful consideration should be given to the potential risks and benefits of G-CSF treatment in neutropenic cancer patients with COVID-19.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹
Article Respiratory System

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Leo Sekine et al.

Summary: This study investigated the effect of convalescent plasma therapy in hospitalized COVID-19 patients. The results showed that convalescent plasma therapy did not result in a higher proportion of clinical improvement compared to standard of care alone.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹
Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

添加到收藏夹
Review Medicine, General & Internal

Immunity to SARS-CoV-2 induced by infection or vaccination

Xaquin Castro Dopico et al.

Summary: Adaptive immune responses are crucial for viral clearance and protection against re-infection, including SARS-CoV-2. The rapid characterization of the immune response to the virus during the first 20 months of the pandemic has provided a detailed understanding. The development and global rollout of effective COVID-19 vaccines have made a significant impact, although challenges remain in terms of equal access.

JOURNAL OF INTERNAL MEDICINE (2022)

添加到收藏夹
Article Respiratory System

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Timothy Devos et al.

Summary: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹
Article Virology

The outcome of COVID-19 in patients with hematological malignancy

Tugce N. Yigenoglu et al.

Summary: This study shows that patients with hematological malignancy have a higher risk of COVID-19-related severe events compared to those without cancer, with higher rates of ICU admission, mechanical ventilation support, and death. It confirms the heightened vulnerability of patients with hematological malignancy during the current pandemic.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹
Editorial Material Immunology

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

Martin Martinot et al.

Summary: A 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia developed a mutation in RdRP (D484Y) following treatment with remdesivir, but was successfully cured after supplementation with convalescent plasma.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Immunology

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Chanu Rhee et al.

Summary: SARS-CoV-2 is most contagious around symptom onset, with infectivity rapidly decreasing to near-zero afterwards; mild-moderately ill patients can safely discontinue isolation after about 10 days, while severely-critically ill and immunocompromised patients may need 15 days. The longest duration associated with replication-competent virus is 20 days.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Hematology

SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study

Andreas Glenthoj et al.

Summary: This prospective study in Danish haematology patients with SARS-CoV-2 infection indicated that older age, severe comorbidities, and critical infection severity were associated with higher mortality rates.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹
Editorial Material Cardiac & Cardiovascular Systems

COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves

Teresa R. Hennona et al.

Summary: MIS-C remains a concerning diagnosis in those infected with SARS-CoV-2, especially as vaccination and natural immunity reduce infection rates. Febrile children with cardiac dysfunction, symptoms resembling Kawasaki disease, or significant gastrointestinal complaints should be thoroughly evaluated in emergency settings. Heightened vigilance and consideration of higher levels of care are recommended for successful outcomes.

PROGRESS IN PEDIATRIC CARDIOLOGY (2021)

添加到收藏夹
Article Medicine, General & Internal

Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab

Carlos X. Rabascall et al.

Summary: Monoclonal antibody treatment has shown promise in mitigating the harmful effects of COVID-19, but its efficacy in patients with prolonged symptoms remains unclear. A unique case presented an immunosuppressed patient who received monoclonal antibodies 54 days after symptom onset, suggesting a potential use for monoclonal antibodies outside of the recommended therapeutic window in certain patient populations.

BMJ CASE REPORTS (2021)

添加到收藏夹
Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹
Meeting Abstract Hematology

COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)

Diana Averbuch et al.

BLOOD (2021)

添加到收藏夹
Correction Oncology

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients (vol 39, pg 1448, 2021)

Patrick Harrington et al.

CANCER CELL (2021)

添加到收藏夹
Article Infectious Diseases

Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?

Antonio Piralla et al.

Summary: Real-time reverse transcription PCR is currently the most sensitive method to detect SARS-CoV-2. In this study, virus isolation was attempted in nasal swabs with low viral load from recovered patients, resulting in a 2.3% culture positivity rate with cytopathic effect detected in nine samples. This study helps to understand true virus replication and residual viral RNA detection in recovered patients.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Virology

Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures

Karoline Leuzinger et al.

Summary: Detecting SARS-CoV-2 is crucial for assessing COVID-19, and manual and automated high-throughput testing were cross-validated. Detection rates decreased after lockdown but increased following relaxation measures, with infected patients being younger than during lockdown.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹
Article Medicine, General & Internal

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study (Publication with Expression of Concern. See vol. 401, pg. 90, 2023)

Chaolin Huang et al.

Summary: This study aimed to investigate the long-term health consequences of discharged COVID-19 patients and associated risk factors, particularly disease severity. Patients with more severe illness during hospitalization showed more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, highlighting the need for targeted interventions for long-term recovery.

LANCET (2021)

添加到收藏夹
Article Oncology

SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients

Gabrielle M. Haeusler et al.

Summary: Although most children with cancer had asymptomatic or mild COVID-19, 13% of patients had severe cases and 3% died. Comorbidity, coinfection, and severe neutropenia may increase the risk of severe disease.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹
Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹
Article Medicine, General & Internal

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial

Marie W. Munch et al.

Summary: In patients with COVID-19 and severe hypoxemia, the use of 12 mg/d of dexamethasone compared to 6 mg/d did not lead to a statistically significant difference in the number of days alive without life support at 28 days. The study may have lacked the power to detect a significant effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹
Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

添加到收藏夹
Article Oncology

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Lorenzo Canti et al.

Summary: Response to SARS-CoV-2 mRNA vaccination in allogeneic hematopoietic stem cell transplantation recipients is influenced by chronic GVHD and rituximab therapy. Immunological markers could assist in identifying allo-HCT patients at risk of poor antibody response to mRNA vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Article Oncology

Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Sheena Mukkada et al.

Summary: The study found that around one fifth of children and adolescents with cancer infected with SARS-CoV-2 developed severe or critical illness, with a higher death rate than in the general pediatric population. Factors associated with treatment modification were different from those associated with disease severity, highlighting the need to raise global awareness of the high risk of severe COVID-19 illness in children and adolescents with cancer. These findings could inform clinical guidelines and improve care practices for this vulnerable population.

LANCET ONCOLOGY (2021)

添加到收藏夹
Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹
Article Medicine, General & Internal

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Review Virology

Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis

Sujan Badal et al.

Summary: COVID-19 is prevalent in pediatric populations with varying symptoms, but children generally have a milder course of the disease with a very favorable prognosis. Laboratory and radiological features are inconsistent, highlighting the need for further research in this area.

JOURNAL OF CLINICAL VIROLOGY (2021)

添加到收藏夹
Letter Biochemistry & Molecular Biology

COVID-19 vaccination: the VOICE for patients with cancer

Astrid A. M. van der Veldt et al.

NATURE MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Review Hematology

COVID-19 convalescent plasma: Interim recommendations from the AABB

Claudia S. Cohn et al.

TRANSFUSION (2021)

添加到收藏夹
Article Critical Care Medicine

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Phillip D. Monk et al.

Summary: The study evaluated the efficacy and safety of using interferon beta-1a to treat COVID-19, with results showing that patients who received treatment had higher and faster recovery rates, providing potential evidence for further clinical trials.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹
Article Critical Care Medicine

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Francois-Xavier Lescure et al.

Summary: This study aimed to evaluate the safety and efficacy of sarilumab in patients with severe or critical COVID-19, but found no significant efficacy in patients admitted to the hospital receiving supplemental oxygen. Future adequately powered trials of targeted immunomodulatory therapies with survival as a primary endpoint are suggested for patients with critical COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹
Article Critical Care Medicine

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open- label, multicentre, randomised, controlled, phase 3 trial

Arvinder S. Soin et al.

Summary: The study recruited 180 patients and found that tocilizumab did not reduce disease progression in patients with moderate to severe COVID-19, but may have some effect in severe cases.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹
Article Multidisciplinary Sciences

SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers

Francesca Rovida et al.

Summary: A study of healthcare workers vaccinated with BNT162b2 vaccine showed an 83% protection rate against SARS-CoV-2 infection in the overall population and 93% in previously infected individuals. Evidence of virus transmission was low, with breakthrough infections mostly asymptomatic or mild, supporting the real-world effectiveness of the vaccine.

NATURE COMMUNICATIONS (2021)

添加到收藏夹
Review Multidisciplinary Sciences

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Victoria Rotshild et al.

Summary: New COVID-19 vaccines from Pfizer and Moderna showed the highest efficacy in preventing symptomatic COVID-19 in adults. There was no significant difference in the prevention of symptomatic disease among the elderly population. mRNA-1273 and Gam-COVID-Vac vaccines were associated with a higher probability of protection against severe COVID-19 compared to other vaccines.

SCIENTIFIC REPORTS (2021)

添加到收藏夹
News Item Medicine, General & Internal

Covid-19: Monoclonal antibodies authorised in US as alternative to vaccines for certain groups

Zosia Kmietowicz

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹
News Item Medicine, General & Internal

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹
News Item Medicine, General & Internal

Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹
Letter Medicine, General & Internal

Sixty-Day Outcomes Among Patients Hospitalized With COVID-19

Vineet Chopra et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹
Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹
Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

添加到收藏夹
Editorial Material Hematology

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Rabah Redjoul et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹
Article Infectious Diseases

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

Alessandra D'Abramo et al.

Summary: Prolonged B-cell depletion caused by anti-CD20 therapy impairs the adaptive immune response, leading to severe manifestations during COVID-19. Two patients under anti-CD20 therapy experienced prolonged and severe COVID-19 but were successfully treated with mAbs targeting the SARS-CoV-2 spike proteins.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Medicine, General & Internal

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman et al.

Summary: This prospective clinical trial investigated the safety and efficacy of the BNT162b2 mRNA vaccine in immunocompromised patients and healthy controls. The vaccine was found to be safe in immunocompromised patients, but with a lower seroconversion rate compared to healthy controls. Additional vaccine doses may be needed to improve immunity in certain immunocompromised patient groups.

EBIOMEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel et al.

Summary: This cohort study in Tel Aviv, Israel, found that vaccination with the Pfizer-BioNTech BNT162b2 vaccine was significantly associated with a lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers more than 7 days after the second dose.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹
Review Infectious Diseases

Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

Chih-Cheng Lai et al.

Summary: The study found that remdesivir can improve the clinical outcomes of patients with COVID-19, with a 5-day regimen likely being sufficient. However, no mortality benefit was observed with remdesivir treatment, and there was no increased risk of adverse events.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹
Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Article Immunology

Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Julien Marlet et al.

Summary: This retrospective study aimed to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in kidney transplant recipients and CLL patients. Results showed a moderate increase in SARS-CoV-2 anti-spike IgG levels after the third dose, but the impact on prevalence of anti-spike IgG & GE; 30 BAU/mL was limited in these immunocompromised patients.

VACCINES (2021)

添加到收藏夹
Article Microbiology

Multicenter Technical Validation of 30 Rapid Antigen Tests for the Detection of SARS-CoV-2 (VALIDATE)

Gilbert Greub et al.

Summary: During the COVID-19 pandemic, technical sensitivities and specificities of 30 different SARS-CoV-2 rapid antigen tests (RATs) were evaluated, with only 50% passing the validation due to issues like lack of sensitivity. It is recommended to conduct thorough validation of RATs before market release to address the high failure rate and ensure accurate testing results.

MICROORGANISMS (2021)

添加到收藏夹
Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹
Review Infectious Diseases

Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis

Nicole Ngai Yung Tsang et al.

Summary: This study systematically compared the diagnostic performance of different clinical specimen collection methods for SARS-CoV-2 infection. Pooled nasal and throat swabs showed the highest sensitivity and positive predictive value, while saliva and nasal swabs also demonstrated good diagnostic performance. Throat swabs had a significantly lower sensitivity and positive predictive value and were not recommended for diagnosis. Self-collection for pooled nasal and throat swabs and nasal swabs did not affect diagnostic accuracy.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

添加到收藏夹
Article Pediatrics

Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2

Erika Molteni et al.

Summary: Most school-aged children in the UK with SARS-CoV-2 infection are asymptomatic or experience mild illness, with longer duration and higher symptom burden observed in older children. Persistence of illness is more common in older children, but symptom burden does not increase over time and most recover within 56 days. Children who test negative for SARS-CoV-2 may also experience prolonged illness with higher symptom burden.

LANCET CHILD & ADOLESCENT HEALTH (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Post-acute COVID-19 syndrome

Ani Nalbandian et al.

Summary: SARS-CoV-2 is responsible for the COVID-19 pandemic, causing global healthcare crises. Recovery from COVID-19 may lead to persistent symptoms and long-term complications, prompting the need for multidisciplinary care and follow-up for survivors.

NATURE MEDICINE (2021)

添加到收藏夹
Review Oncology

Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review

Jagdish Prasad Meena et al.

Summary: The impact of COVID-19 on pediatric oncology patients is more severe in terms of severity, morbidity, and mortality compared to the general pediatric population, with a higher percentage of severe cases.

PEDIATRIC BLOOD & CANCER (2021)

添加到收藏夹
Article Immunology

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study

Chiara Sepulcri et al.

Summary: Immunocompromised patients can have prolonged shedding of SARS-CoV-2 and clinical relapses of COVID-19, with differences in cell immune dynamics and absence of virus-specific antibodies detected.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Immunology

Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019

James Regan et al.

Summary: The dynamics of SARS-CoV-2 remain understudied, but early systemic seeding of the virus was observed in hospitalized individuals. Remdesivir treatment was associated with faster viral decay in the body.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹
Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

添加到收藏夹
Article Hematology

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington et al.

Summary: This study found that most patients with CML developed antibodies and polyfunctional T-cell responses after receiving a single dose of the SARS-CoV-2 BNT162b2 vaccine, demonstrating good immunogenicity in this patient population compared to those with solid tumors or lymphoid hematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹
Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹
Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

添加到收藏夹
Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹
Letter Oncology

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

Mario Mairhofer et al.

CANCER CELL (2021)

添加到收藏夹
Article Infectious Diseases

Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study

Francesca Rovida et al.

Summary: The study evaluated the protective effect of SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity induced by natural infection against SARS-CoV-2 infection. The results showed that immunity from natural infection can reduce the risk of secondary infection and alleviate symptoms.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹
Article Medicine, General & Internal

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹
Article Microbiology

Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection

Karoline Leuzinger et al.

Summary: Commercially available SARS-CoV-2-directed antibody assays showed substantial agreement, with interpretation of results depending on postdiagnosis time and choice of viral antigen. The presence of systemic SARS-CoV-2-specific antibodies may predict recovery from viral injury and clearance of mucosal replication.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹
Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

添加到收藏夹
Article Oncology

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Per Ljungman et al.

Summary: The study reveals that COVID-19 patients who have undergone allogeneic or autologous hematopoietic cell transplantation are at high risk of developing lower respiratory tract disease, requiring ICU admission, and have increased mortality rates.

LEUKEMIA (2021)

添加到收藏夹
Article Oncology

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Ilana Levy et al.

Summary: This study found that COVID-19 infection is particularly severe in patients with hematological malignancies. Factors like age over 70, hypertension, and active hematological cancer treatment may increase the risk of severe disease or hospitalization, while remdesivir stands out as the most effective treatment among those examined.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹
Article Oncology

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Tomas Palanques-Pastor et al.

Summary: This multicenter observational study found a higher mortality rate in AML patients with SARS-CoV-2 infection. Factors influencing mortality included age, gender, active leukemia, severity of symptoms, etc. Certain medications and biochemical markers may have a protective effect in lowering the mortality rate.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Evdoxia Kyriazopoulou et al.

Summary: The SAVE-MORE phase 3 study demonstrated the efficacy of anakinra, an IL-1 alpha/beta inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, showing significant reduction in clinical deterioration and decreased 28-day mortality.

NATURE MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

Frederick K. Korley et al.

Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Virology

Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail

Arnaud C. Drouin et al.

Summary: A 59-year-old male with follicular lymphoma was hospitalized with a COVID-19 infection and successfully cleared the virus after treatment with REGEN-COV antibodies. Monitoring virus mutations and coordinating a multidisciplinary team of experts were critical during the treatment process.

VIRUSES-BASEL (2021)

添加到收藏夹
Letter Oncology

Long-term follow-up of recovered MPN patients with COVID-19

Tiziano Barbui et al.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹
Article Medicine, General & Internal

Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis

Lukas E. Brummer et al.

Summary: A systematic review and meta-analysis was conducted to evaluate the clinical accuracy of commercially available Ag-RDTs for SARS-CoV-2. The study found that Ag-RDTs can detect the vast majority of infected individuals in the early phase of the disease and those with high viral load, making them valuable diagnostic tools. However, concerns were raised regarding bias across datasets and the need for standardization in conducting and reporting clinical accuracy studies for improved comparability and data utilization.

PLOS MEDICINE (2021)

添加到收藏夹
Article Critical Care Medicine

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Jean-Claude Tardif et al.

Summary: The study aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹
Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹
Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

添加到收藏夹
Article Oncology

Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients

Martina Chiarucci et al.

Summary: The efficacy of Covid-19 vaccine in HSCT recipients remains uncertain. This study showed that prior Rituximab in autologous HSCT and cyclosporine administration in allogeneic HSCT negatively impacted antibody response. Additionally, increased numbers of CD19+ B lymphocytes and CD56+ natural killer cells correlated significantly with antibody response.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹
Article Immunology

Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report

Pankaj Luitel et al.

Summary: This study reported a case of a patient with hypogammaglobulinemia who was successfully treated with REGN-COV2 for persistent COVID-19 pneumonia. Targeted antiviral antibodies may play a significant role in managing immunocompromised patients infected with SARS-CoV-2.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹
Letter Medicine, General & Internal

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Amandine Le Bourgeois et al.

JAMA NETWORK OPEN (2021)

添加到收藏夹
Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry et al.

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

添加到收藏夹
Article Hematology

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

Haris Ali et al.

Summary: This study retrospectively reviewed 113 allogeneic hematopoietic stem cell transplant (HCT) patients who received SARS-CoV2 vaccines, and found that the vaccines were well tolerated in this group. Common side effects included myalgias/arthralgias, fatigue, injection site pain, and liver function abnormalities, as well as neutropenia and other hematologic issues.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹
Article Hematology

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Ron Ram et al.

Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹
Article Health Care Sciences & Services

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Bjoern Jensen et al.

Summary: The study indicates that treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients may result in the rapid development of immune escape variants, which could have significant implications for the effectiveness of vaccination and antibody-based therapies.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹
Review Critical Care Medicine

Diagnosis of severe respiratory infections in immunocompromised patients

Elie Azoulay et al.

INTENSIVE CARE MEDICINE (2020)

添加到收藏夹
Article Hematology

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Steven P. Treon et al.

BLOOD (2020)

添加到收藏夹
Article Biophysics

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Per Ljungman et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹
Editorial Material Cardiac & Cardiovascular Systems

COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal

Hasan K. Siddiqi et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)

添加到收藏夹
Review Medicine, General & Internal

COVID-19 diagnosis and management: a comprehensive review

Giuseppe Pascarella et al.

JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹
Article Medicine, General & Internal

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer et al.

LANCET (2020)

添加到收藏夹
Article Oncology

COVID-19 in persons with chronic myeloid leukaemia

Weiming Li et al.

LEUKEMIA (2020)

添加到收藏夹
Editorial Material Oncology

Provision of cancer care during the COVID-19 pandemic

James Spicer et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹
Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Public, Environmental & Occupational Health

Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study

Benjamin J. Cowling et al.

LANCET PUBLIC HEALTH (2020)

添加到收藏夹
Article Pathology

Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

Eric Salazar et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

添加到收藏夹
Article Hematology

Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies

Jose Maria Sanchez-Pina et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹
Letter Hematology

COVID-19 in patients with hematological malignancies: A retrospective case series

Maria-Stefania Infante et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)

添加到收藏夹
Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹
Article Oncology

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfo et al.

LEUKEMIA (2020)

添加到收藏夹
Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

添加到收藏夹
Article Multidisciplinary Sciences

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jerome Hadjadj et al.

SCIENCE (2020)

添加到收藏夹
Article Oncology

Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study

Donna R Rivera et al.

Cancer Discovery (2020)

添加到收藏夹
Review Medicine, General & Internal

Drug treatments for covid-19: living systematic review and network meta-analysis

Reed A. C. Siemieniuk et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹
Review Infectious Diseases

Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review

Chih-Cheng Lai et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹
Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹
Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹
Article Oncology

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio Garcia-Suarez et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹
Article Oncology

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee et al.

LANCET ONCOLOGY (2020)

添加到收藏夹
Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Editorial Material Medicine, General & Internal

A living WHO guideline on drugs for covid-19

Francois Lamontagne et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹
Article Oncology

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Jose Luis Pinana et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹
Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood et al.

BLOOD ADVANCES (2020)

添加到收藏夹
Review Infectious Diseases

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Li Jiang et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹
Article Immunology

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

Chun-Kit Yuen et al.

EMERGING MICROBES & INFECTIONS (2020)

添加到收藏夹
Review Microbiology

Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs

Michael G. Ison et al.

CLINICAL MICROBIOLOGY REVIEWS (2019)

添加到收藏夹
Review Cell Biology

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Shi-fang Li et al.

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)

添加到收藏夹
Review Infectious Diseases

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

A. J. Ullmann et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.